As a network of the leading experts in psoriasis, we convene, collaborate and partner with all stakeholders in order to exchange knowledge and influence how patients are treated around the world. Below are our current corporate members who support and collaborate on our work.
Gold MEMBERS
For more information about IPC's Corporate Members Program, please contact Tina Burke, Director, Corporate Relations, at Tina.Burke@psoriasiscouncil.com
now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News